|By PR Newswire||
|April 2, 2014 10:10 AM EDT||
SANTA MONICA, Calif., April 2, 2014 /PRNewswire/ -- Kite Pharma, Inc. (Kite), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for cancer, today announced the appointment of Arie Belldegrun, M.D., FACS, as President and Chief Executive Officer. Dr. Belldegrun, who is also a founder of Kite, will continue in his current role as Chairman of the Company.
"Dr. Belldegrun has had a distinguished 18-year tenure in the life sciences industry, having been closely involved with the founding and advancement of successful private and public biopharmaceutical companies," commented David Bonderman, speaking on behalf of Kite's Board of Directors. "We are very pleased that he will take on his new role at Kite as the Company continues its momentum and further advances its broadly enabling platform in cancer immunotherapy."
Prior to founding Kite, Dr. Belldegrun was the founding Vice-Chairman of the board of directors and Chairman of the scientific advisory board of Cougar Biotechnology, acquired by Johnson & Johnson in 2009 in a $970 million transaction. Previously, Dr. Belldegrun founded Agensys and served as Chairman of the board of directors. He also currently serves as Chairman of Arno Therapeutics, Inc., and as a board member of Teva Pharmaceutical Industries Ltd., SonaCare Medical, and TheraCoat. In addition, Dr. Belldegrun is Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA.
Dr. Belldegrun completed his M.D. training at the Hebrew University Hadassah Medical School in Jerusalem, his post-doctoral in immunology research at the Weizmann Institute of Science (Israel) and his residency in urologic surgery at the Brigham and Women's Hospital, Harvard Medical School. He also completed a research fellowship in surgical oncology and immunotherapy under Steven A. Rosenberg, M.D., Ph.D., at the National Cancer Institute/NIH. Dr. Belldegrun has authored several books in oncology and more than 400 scientific and medical papers related to urologic cancers, immunotherapy, gene therapy, and cancer vaccines. He is certified by the American Board of Urology and is a Fellow of the American College of Surgeons and of the American Association of Genitourinary Surgeons.
About Kite Pharma
Kite Pharma, Inc. (Kite) is a privately held clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a cooperative research and development agreement (CRADA), Kite is advancing a pipeline of proprietary eACT™ product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite's management team has a proven track record of building successful biotechnology companies and successfully developing cutting-edge immunotherapies and oncology treatments. Kite is based in Santa Monica, CA.
Cynthia M. Butitta
Chief Financial Officer and Chief Operating Officer
SOURCE Kite Pharma, Inc.
Dec. 9, 2016 12:45 AM EST Reads: 5,105
Dec. 9, 2016 12:45 AM EST Reads: 1,197
Dec. 9, 2016 12:30 AM EST Reads: 876
Dec. 9, 2016 12:00 AM EST Reads: 687
Dec. 9, 2016 12:00 AM EST Reads: 1,171
Dec. 8, 2016 09:45 PM EST Reads: 1,237
Dec. 8, 2016 09:15 PM EST Reads: 1,670
Dec. 8, 2016 09:15 PM EST Reads: 961
Dec. 8, 2016 08:30 PM EST Reads: 1,891
Dec. 8, 2016 07:45 PM EST Reads: 333
Dec. 8, 2016 07:15 PM EST Reads: 392
Dec. 8, 2016 06:45 PM EST Reads: 957
Dec. 8, 2016 05:45 PM EST Reads: 951
Everyone knows that truly innovative companies learn as they go along, pushing boundaries in response to market changes and demands. What's more of a mystery is how to balance innovation on a fresh platform built from scratch with the legacy tech stack, product suite and customers that continue to serve as the business' foundation. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, discussed why and how ReadyTalk diverted from healthy revenue and mor...
Dec. 8, 2016 05:45 PM EST Reads: 1,726
As data explodes in quantity, importance and from new sources, the need for managing and protecting data residing across physical, virtual, and cloud environments grow with it. Managing data includes protecting it, indexing and classifying it for true, long-term management, compliance and E-Discovery. Commvault can ensure this with a single pane of glass solution – whether in a private cloud, a Service Provider delivered public cloud or a hybrid cloud environment – across the heterogeneous enter...
Dec. 8, 2016 05:00 PM EST Reads: 1,822